Cover Image
市場調查報告書

全球再生醫療的聯盟情形:契約動向、企業、財務及預測

Global Regenerative Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 263732
出版日期 內容資訊 英文 660 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球再生醫療的聯盟情形:契約動向、企業、財務及預測 Global Regenerative Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts
出版日期: 2016年09月01日 內容資訊: 英文 660 Pages
簡介

本報告提供全球再生醫療、幹細胞治療市場上企業聯盟的締結趨勢與其內容(聯盟條件)相關分析,近幾年的企業聯盟/交易形成情形特徵,各交易類型、各適應症、各技術種類詳細趨勢,平均交易條件,代表性資本交易的概要,大醫藥品企業趨勢,近幾年的聯盟交易一覽與其明細等資訊彙整為您概述為以下內容。

摘要整理

第1章 簡介

第2章 再生醫療、幹細胞治療相關的交易形成趨勢

  • 簡介
  • 過去數年的再生醫療的聯盟趨勢
  • 聯盟最積極的企業
  • 再生醫療、幹細胞相關的聯盟:各交易類型
  • 再生醫療、幹細胞相關的聯盟:各治療領域
  • 聯盟的平均交易條件
    • 交易總額 (headline values)
    • 預付款金
    • 階段性付款
    • 權利金費率

第3章 代表性的聯盟交易

  • 簡介
  • 最有效的交易:各金額

第4章 大醫藥品企業的聯盟交易

  • 簡介
  • 大醫藥品企業的合作交易的有效利用方法
  • 大醫藥品企業各公司簡介

第5章 再生醫療的交易形成一覽

  • 簡介
  • 交易形成一覽

第6章 各技術種類的交易形成

第7章 聯盟資源中心

  • 線上聯盟
  • 聯盟趨勢
  • 相關資料

附錄

  • 附錄1:企業名順序(A∼Z)
  • 附錄2:各臨床實驗階段
    • 藥物研發
    • 前臨床
    • 第一階段
    • 第二階段
    • 第三階段
    • 認證中
    • 已上市
    • 處方(製劑)設計
  • 附錄3:各交易類型
    • 資產購買
    • 大型製藥企業的轉出授權
    • 共同開發
    • 共同研究開發(R&D)
    • 共同販賣
    • 共同促銷
    • 共同研究開發協定(CRADA)
    • 交叉許可
    • 開發
    • 流通
    • 股票購買
    • 評估
    • 津貼
    • 合資企業
    • 許可證
    • 訴訟
    • 製造
    • 行銷
    • 物質移動
    • 選擇
    • 推銷
    • 研究
    • 調停
    • 衍生公司
    • 再授權
    • 供給
    • 技術移交
    • 契約結束
    • 保證
  • 附錄4:各治療領域
  • 附錄5:交易種類定義

Wildwood 關於Ventures

  • Current Partnering
  • Current Agreements
  • Current Partnering 最新報告

圖表一覽

附錄

  • 簡介
  • 附錄1 聯盟交易的一覽:各企業名(A∼Z,過去5年份)
  • 附錄2 聯盟交易的一覽:各開發階段(過去5年份)
  • 附錄3 聯盟交易的一覽:各交易類型(過去5年份)
  • 附錄4 聯盟交易的一覽:各治療領域(過去5年份)
  • 附錄5 聯盟資源中心

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2116

The ‘Global Regenerative Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts’ report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies

The ‘Global Regenerative Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts’ report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in regenerative medicine
  • Deal terms analysis
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for regenerative medicine and stem cells

The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.

The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 950 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Regenerative Medicine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Regenerative Medicine dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Regenerative Medicine deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Regenerative Medicine dealmaking with a brief summary followed by a comprehensive listing of Regenerative Medicine deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Regenerative Medicine partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Regenerative Medicine partnering deals signed and announced since Jan 2010. The chapter is organized by specific Regenerative Medicine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Regenerative Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Regenerative Medicine partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Regenerative Medicine technologies and products.

Key benefits

‘Global Regenerative Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts’ provides the reader with the following key benefits:

  • In-depth understanding of Regenerative Medicine deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Regenerative Medicine agreements with numerous real life case studies
  • Detailed access to actual Regenerative Medicine contracts entered into by leading biopharma companies
  • Identify most active Regenerative Medicine dealmakers since 2010
  • Insight into terms included in a Regenerative Medicine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Regenerative Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts’ is intended to provide the reader with an in-depth understanding and access to Regenerative Medicine trends and structure of deals entered into by leading companies worldwide.

Regenerative Medicine Partnering Terms and Agreements includes:

  • Trends in Regenerative Medicine dealmaking in the biopharma industry since 2010
  • Analysis of Regenerative Medicine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Regenerative Medicine deals
  • Access to Regenerative Medicine contract documents
  • Leading Regenerative Medicine deals by value since 2010
  • Most active Regenerative Medicine dealmakers since 2010

In ‘Global Regenerative Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts’, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Regenerative Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts’ report provides comprehensive access to available deals and contract documents for over 950 Regenerative Medicine deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Regenerative Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts’ provides the reader with the following key benefits:

  • In-depth understanding of Regenerative Medicine deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Regenerative Medicine agreements with numerous real life case studies
  • Detailed access to actual Regenerative Medicine contracts entered into by leading biopharma companies
  • Identify most active Regenerative Medicine dealmakers since 2010
  • Insight into terms included in a Regenerative Medicine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Regenerative Medicine dealmaking

  • 2.1. Introduction
  • 2.2. Regenerative Medicine partnering over the years
  • 2.3. Most active Regenerative Medicine dealmakers
  • 2.4. Regenerative Medicine partnering by deal type
  • 2.5. Regenerative Medicine partnering by therapy area
  • 2.6. Deal terms for Regenerative Medicine partnering
    • 2.6.1 Regenerative Medicine partnering headline values
    • 2.6.2 Regenerative Medicine deal upfront payments7
    • 2.6.3 Regenerative Medicine deal milestone payments
    • 2.6.4 Regenerative Medicine royalty rates

Chapter 3 - Leading Regenerative Medicine deals

  • 3.1. Introduction
  • 3.2. Top Regenerative Medicine deals by value

Chapter 4 - Most active Regenerative Medicine dealmakers

  • 4.1. Introduction
  • 4.2. Most active Regenerative Medicine dealmakers
  • 4.3. Most active Regenerative Medicine partnering company profiles

Chapter 5 - Regenerative Medicine contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Regenerative Medicine contracts dealmaking directory

Chapter 6 - Regenerative Medicine dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Regenerative Medicine deals by company A-Z
  • Appendix 2 - Regenerative Medicine deals by stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation
  • Appendix 3 - Regenerative Medicine deals by deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty
  • Appendix 4 - Regenerative Medicine deals by therapy area
  • Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Regenerative Medicine partnering since 2010
  • Figure 2: Active Regenerative Medicine dealmaking activity- 2010 to 2016
  • Figure 3: Regenerative Medicine partnering by deal type since 2010
  • Figure 4: Regenerative Medicine partnering by disease type since 2010
  • Figure 5: Regenerative Medicine deals with a headline value
  • Figure 6: Regenerative Medicine deals with an upfront value
  • Figure 7: Regenerative Medicine deals with a milestone value
  • Figure 8: Regenerative Medicine deals with a royalty rate value
  • Figure 9: Top Regenerative Medicine deals by value since 2010
  • Figure 10: Most active Regenerative Medicine dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top